Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experienc
| Autor: | Hedwig Kasparu, Peter Kalhs, Niklas Zojer, Gudrun Russ, Konrad Namberger, Konrad Rosskopf, Werner Linkesch, Nina Worel, Ernst Schloegl, David Nachbaur, Peter Neumeister, Volker Witt, Hildegard Greinix |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male Benzylamines Receptors CXCR4 medicine.medical_specialty Adolescent Lymphoma Immunology Antigens CD34 Cyclams Transplantation Autologous Gastroenterology Young Adult Heterocyclic Compounds Internal medicine Granulocyte Colony-Stimulating Factor medicine Humans Immunology and Allergy Autologous transplantation Leukapheresis Melphalan Hematopoietic Stem Cell Mobilization Multiple myeloma Aged business.industry Plerixafor Hematopoietic Stem Cell Transplantation Hematology Middle Aged Hematopoietic Stem Cells medicine.disease Combined Modality Therapy Surgery Granulocyte colony-stimulating factor Transplantation Austria Immunoglobulin G Drug Therapy Combination Female Stem cell Multiple Myeloma business medicine.drug |
| Zdroj: | Transfusion. 51:968-975 |
| ISSN: | 0041-1132 |
| DOI: | 10.1111/j.1537-2995.2010.02896.x |
| Popis: | Background Plerixafor in combination with granulocyte-colony-stimulating factor (G-CSF) has been shown to enhance stem cell mobilization in patients with multiple myeloma, non-Hodgkin's lymphoma, and Hodgkin's disease who demonstrated with previous mobilization failure. In this named patient program we report the Austrian experience in insufficiently mobilizing patients. Study design and methods Twenty-seven patients from eight Austrian centers with a median (range) age of 58 (19-70) years (18 female, nine male) were included in the study. Plerixafor was limited to patients with previous stem cell mobilization failure and was given in the evening of Day 4 of G-CSF application. Results A median increase of circulating CD34+ cells within 10 to 11 hours from administration of plerixafor by a factor of 4.7 over baseline was noted. Overall, 20 (74%) patients reached more than 10 × 10(6) CD34+ cells/L in the peripheral blood, resulting in 17 (63%) patients collecting at least 2 × 10(6) CD34+ cells/kg body weight (b.w.; median, 2.6 × 10(6) CD34+ cells/kg b.w.; range, 0.08 × 10(6) -8.07 × 10(6) ). Adverse events of plerixafor were mild to moderate and consisted of gastrointestinal side effects and local reactions at the injection site. Thirteen (48%) patients underwent autologous transplantation receiving a median of 2.93 × 10(6) CD34+ cells/kg (range, 1.46 × 10(6) -5.6 × 10(6) ) and showed a trilinear engraftment with a median neutrophil recovery on Day 12 and a platelet recovery on Day 14. Conclusion Our study confirms previous investigations showing that plerixafor in combination with G-CSF is an effective and well-tolerated mobilization regimen with the potential of successful stem cell collection in patients with previous mobilization failure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text